Biostatisticians and regulatory affairs leads use this agent when drafting the regulatory justification for an adaptive design — including seamless Phase II/III, response-adaptive randomisation, or Bayesian adaptive designs — for submission to FDA or EMA as part of a pre-submission meeting package or protocol, where the statistical complexity must be translated into regulatory language that a non-statistician reviewer can evaluate.